Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.
- As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.
- Addex retains exclusive rights to develop its own independent GABAB PAM program and is advancing compounds in Charcot-Marie-Tooth type 1A neuropathy (CMT1A), chronic cough and pain.
- Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
- Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.